| Literature DB >> 33730755 |
Joana Torres1,2, Jonas Halfvarson3, Iago Rodríguez-Lago4, Charlotte R H Hedin5,6, Tine Jess7,8, Marla Dubinsky9, Kenneth Croitoru10,11, Jean-Frédéric Colombel12.
Abstract
Inflammatory bowel disease [IBD] is a complex chronic disorder with no clear aetiology and no known cure. Despite recent advances in overall disease management and improved therapeutics, patients with IBD still experience a substantial burden. Furthermore, as the incidence continues to increase in developing areas of the world, it is expected that the burden of IBD to society will increase and exert tremendous pressure on health care systems worldwide. Therefore, new strategies to prevent the global increase of IBD are urgently required. Data are being progressively acquired on the period preceding disease diagnosis, which support the concept that IBD has a preclinical period that may reveal the triggers of disease and may be amenable to early intervention. Having a better knowledge of this preclinical period will increase the potential not only for improved understanding of disease pathogenesis and improved therapeutics, but also for disease prediction and prevention.Entities:
Keywords: Crohn’s disease; Inflammatory bowel disease; biomarkers; precision medicine; prediction; prevention; ulcerative colitis
Mesh:
Year: 2021 PMID: 33730755 DOI: 10.1093/ecco-jcc/jjab048
Source DB: PubMed Journal: J Crohns Colitis ISSN: 1873-9946 Impact factor: 9.071